This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zalbin

GlaxoSmithKline plc

Drug Names(s): ABF656, albinterferon alfa-2b, Albumin-Interferon alpha-2b, Albuferon, Joulferon (EU)

Description: Albuferon is a fusion protein of interferon alpha and albumin. The agent retains the biological activity of the interferon, while the albumin increases the half-life of drug activity in the patient. Albuferon is one of several albumin fusion proteins being developed by HGSI.

Deal Structure: In June 2006, Human Genome (HGS) announced a worldwide licensing agreement with Novartis for the development and commercialization of Albuferon for chronic hepatitis C and all other uses. Under the agreement, HGS and Novartis will co-commercialize Albuferon in the United States, and will share U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization outside the U.S. and will pay HGS a royalty on those sales. HGS and Novartis will share equally in clinical development costs. HGS will receive an upfront fee of $45 million. Clinical development, commercial milestone and other payments to HGS could total as much as $507.5 million, including $47.5 million when the first patient is dosed in a Phase III clinical trial. HGS will have primary responsibility for the bulk manufacture of Albuferon.

In July 2012, GlaxoSmithKline and Human Genome Sciences entered into a definitive agreement under which GSK will acquire HGS for US$14.25 per...See full deal structure in Biomedtracker

Partners: Novartis AG


Zalbin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug